Adalimumab in the management of Behçet’s disease

References

• IshigatsuboYBehçet’s Disease: From Genetics to TherapiesTokyo, JapanSpringer2015
   Google Scholar
• Al-OtaibiLMPorterSRPoateTWBehçet’s disease: a reviewJ Dent Res200584320922215723859
   PubMed Web of Science ®Google Scholar
• MizukiNOtaMYabukiKLocalization of the pathogenic gene of Behçet’s disease by microsatellite analysis of three different populationsInvest Opthalmol Vis Sci20004137023708
   PubMed Web of Science ®Google Scholar
• International Study Group for Behcet’s DiseaseCriteria for diagnosis of Behçet’s diseaseLancet1990335107810801970380
   PubMed Web of Science ®Google Scholar
• Behçet’s Disease Research Committee of JapanBehcet’s disease: guide to diagnosis of Behcet’s diseaseJpn J Ophthalmol197418291294
   Google Scholar
• International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD)DavatchiFAssaad-KhalilSCalamiaKTThe International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteriaJ Eur Acad Dermatol Venereol201328333834723441863
   PubMed Web of Science ®Google Scholar
• RemmersEFCosanFKirinoYGenome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s diseaseNat Genet201042869870220622878
   PubMed Web of Science ®Google Scholar
• MizukiNMeguroAOtaMGenome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility lociNat Genet201042870370620622879
   PubMed Web of Science ®Google Scholar
• KirinoYBertsiasGIshigatsuboYGenome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1Nat Genet201345220220723291587
   PubMed Web of Science ®Google Scholar
• DireskeneliHInnate and adaptive responses to heat shock proteins in Behçet’s diseaseGenet Res Int20132013116
   Google Scholar
• TanakaTYamakawaNKoikeNSuzukiJMizunoFUsuiMBehçet’s disease and antibody titers to various heat-shock protein 60sOcul Immunol Inflamm199972697410420201
   PubMed Web of Science ®Google Scholar
• ZouboulisCCKötterIDjawariDEpidemiological features of Adamantiades-Behçet’s disease in Germany and in EuropeYonsei Med J1997384114229509911
   PubMedGoogle Scholar
• MisumiMHagiwaraETakenoMCytokine production profile in patients with Behçet’s disease treated with infliximabCytokine200324521021814596817
   PubMed Web of Science ®Google Scholar
• YamashitaNKaneokaHKanekoSRole of γδ T lymphocytes in the development of Behçet’s diseaseClin Exp Immunol19971072412479030859
   PubMed Web of Science ®Google Scholar
• KitaichiNMiyazakiAIwataDOhnoSStanfordMRChamsHOcular features of Behçet disease: an international collaborative studyBr J Ophthalmol200791121579158218024808
   PubMed Web of Science ®Google Scholar
• HatemiGSilmanABangDEULAR recommendations for the management of Behçet diseaseAnn Rheum Dis2008671656166218245110
   PubMed Web of Science ®Google Scholar
• OkadaAAGotoHOhnoSMochizukiMfor the Ocular Behçet Disease Research Group of JapanMulticenter study of infliximab for refractory uveoretinitis in Behçet diseaseArch Ophthalmol201213059259822652845
   PubMed Web of Science ®Google Scholar
• TakeuchiMKezukaTSugaiSEvaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet disease: a multicenter studyOphthalmology2014121101877188424950593
   PubMed Web of Science ®Google Scholar
• OhnoSNakamuraSHoriSEfficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitisJ Rheumatol2004311362136815229958
   PubMed Web of Science ®Google Scholar
• NiccoliLNanniniCBenucciMLong-term efficacy of infliximab in refractory posterior uveitis of Behçet disease: a 24-month follow-up studyRheumatology20074671161116417478466
   PubMed Web of Science ®Google Scholar
• GiardinaAFerranteACicciaFVadalàMGiardinaETrioloGOne year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugsRheumatol Int2009311333719859715
   PubMed Web of Science ®Google Scholar
• Al-RayesHAl-SwailemRAl-BalawiMAl-DohayanNAl-ZaidiSTariqMSafety and efficacy of infliximab therapy in active Behçet’s uveitis: an open-label trialRheumatol Int2008291535718496694
   PubMed Web of Science ®Google Scholar
• Al-RashidiSAl-FawazAKangaveDAbu El-AsrarAMLong-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximabOcul Immunol Inflamm201321646847423734940
   PubMed Web of Science ®Google Scholar
• Levy-ClarkeGJabsDAReadRWExpert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disordersOphthalmology2014121378579624359625
   PubMed Web of Science ®Google Scholar
• OlivieriILeccesePD’AngeloSEfficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximabClin Exp Rheumatol20112967S54S5721968237
   PubMedGoogle Scholar
• AdánAHernandezVOrtizSEffects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusionsInt Ophthalmol201030557758120490893
   PubMed Web of Science ®Google Scholar
• Diaz-LlopisMGarcía-DelpechSSalomDAdalimumab therapy for refractory uveitis: a pilot studyJ Ocul Pharmacol Ther200824335136118476805
   PubMed Web of Science ®Google Scholar
• CataláJCFernandezCCCidAREfficacy of adalimumab in Behçet’s disease. Description of 6 casesRhematol Clin201174258261
   Google Scholar
• van LaarJAMissottenTvan DaelePLJamnitskiABaarsmaGSvan HagenPMAdalimumab: a new modality for Behçet’s disease?Ann Rheum Dis200766456556617124248
   PubMed Web of Science ®Google Scholar
• BawazeerARaffaLHClinical experience with adalimumab in the treatment of ocular Behçet diseaseOcul Immunol Inflamm201018322623220482404
   PubMed Web of Science ®Google Scholar
• InterlandiELeccesePOlivieriIAdalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up studyClin Exp Rheumatol20143284S58S6225005224
   PubMedGoogle Scholar
• LeccesePLatanzaLD’AngeloSPadulaAOlivieriIEfficacy of switching to adalimumab in a patient with refractory uveitis of Behçet’s disease to infliximabClin Exp Rheumatol20112967S9321813069
   PubMedGoogle Scholar
• MushtaqBSaeedTSitunayakeRDMurrayPIAdalimumab for sight-threatening uveitis in Behçet’s diseaseEye200721682482516601736
   PubMed Web of Science ®Google Scholar
• TakaseKOhnoSIdeguchiHUchioETakenoMIshigatsuboYSuccessful switching to adalimumab in an infliximab-allergic patient with severe Behçet’s disease-related uveitisRheumatol Int201131224324519816689
   PubMed Web of Science ®Google Scholar
• Callejas-RubioJLSánchez-CanoDSerranoJLOrtego-CentenoNAdalimumab therapy for refractory uveitis: a pilot studyJ Ocul Pharmacol Ther200824661361419049264
   PubMed Web of Science ®Google Scholar
• FrederiksenMTAinsworthMABrynskovLThomsenOOBendtzenKSteenholdtCAntibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBDInflamm Bowel Dis2014201714172125069030
   PubMed Web of Science ®Google Scholar
• TuncRKeymanEMelikogluMFreskoIYaziciHTarget organ associations in Turkish patients with Behçet’s disease: a cross sectional study by exploratory factor analysisJ Rheumatol2002292393239612415598
   PubMed Web of Science ®Google Scholar
• EbertECGastrointestinal manifestations of Behçet’s diseaseDig Dis Sci200854220120718594975
   PubMed Web of Science ®Google Scholar
• ChenYCChangHWClinical characteristics of Behçet’s disease in southern TaiwanJ Microbiol Immunol Infect200134320721011605813
   PubMedGoogle Scholar
• LankowskiJCrombieIJankowskiRBehçet’s syndromePostgrad Med J1992685665701437955
   PubMedGoogle Scholar
• CheonJHHanDSParkJYDevelopment, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s diseaseInflamm Bowel Dis201117260561320848515
   PubMed Web of Science ®Google Scholar
• HisamatsuTUenoFMatsumotoTThe 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodiesJ Gastroenterol201349115616223955155
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology2012142225726522062358
   PubMed Web of Science ®Google Scholar
• ColombelJFSchwartzDASandbornWJAdalimumab for the treatment of fistulas in patients with Crohn’s diseaseGut20095894094819201775
   PubMed Web of Science ®Google Scholar
• LiYHanZWangXCombination therapy of infliximab and thalidomide for refractory entero-Behçet’s disease: a case reportGastroenterology2013131671623280118
   PubMedGoogle Scholar
• KappenJHMensinkPBLesterhuisWMycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet’s disease, evaluated with enteroscopyAm J Gastroenterol2008103123213321419086980
   PubMed Web of Science ®Google Scholar
• KinoshitaHKunisakiRYamamotoHEfficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medicationIntern Med2013521855186223994973
   PubMed Web of Science ®Google Scholar
• LeeJHCheonJHJeonSWEfficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective studyInflamm Bowel Dis20131991833183823702810
   PubMed Web of Science ®Google Scholar
• IwataSSaitoKYamaokaKEfficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s diseaseMod Rheumatol201021218419121052764
   PubMed Web of Science ®Google Scholar
• ChungSHIntestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitisWorld J Gastroenterol201319325389539223983446
   PubMed Web of Science ®Google Scholar
• AikawaNEGonçalvesCSilvaCAGonçalvesCBonfáEde CarvalhoJFLate response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet’s diseaseRheumatol Int20093181097109920012049
   PubMed Web of Science ®Google Scholar
• De CassanCDe VroeyBDussaultCHachullaEBucheSColombelJ-FSuccessful treatment with adalimumab in a familial case of gastrointestinal Behçet’s diseaseJ Crohns Colitis20115436436821683309
   PubMed Web of Science ®Google Scholar
• AriyachaipanichABerkelhammerCNicolaHIntestinal Behçet’s disease: maintenance of remission with adalimumab monotherapyInflamm Bowel Dis200915121769177119177427
   PubMed Web of Science ®Google Scholar
• ShimizuYTakedaTMatsumotoRClinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet diseaseNihon Shokakibyo Gakkai Zasshi20121095774780 Japanese22688103
   PubMedGoogle Scholar
• TanidaSInoueNKobayashiKAdalimumab for the treatment of Japanese patients with intestinal Behçet diseaseClin Gastroenterol Hepatol2014111
   Web of Science ®Google Scholar
• BelzuneguiJLópezLPaniaguaIIntxaustiJJMaízOEfficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet’s diseaseClin Exp Rheumatol20082650S133S13419026138
   PubMedGoogle Scholar
• RobinsonABGallentineWBRabinovichCEPediatric neuro-Behçet’s disease responsive to adalimumabPediatr Neurol201043429129320837311
   PubMed Web of Science ®Google Scholar
• SchreiberBENoorNJuliCFHaskardDOResolution of Behçet’s syndrome associated pulmonary arterial aneurysms with infliximabSemin Arthritis Rheum201141348248721546064
   PubMed Web of Science ®Google Scholar
• EndoLMRoweSMRompRLBuckmasterMAAtkinsonTPPulmonary aneurysms and intracardiac thrombi due to Behçet’s disease in an African–American adolescent with oculocutaneous albinismClin Rheumatol20062691537153917047893
   PubMed Web of Science ®Google Scholar
• BakiKVilligerPMJenniDMeyerTBeerJHBehçet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatmentAnn Rheum Dis200665111531153217038456
   PubMed Web of Science ®Google Scholar
• LeeSWLeeSYKimKNJungJKChungWTAdalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case reportClin Rheumatol2009291919319816754
   PubMed Web of Science ®Google Scholar